Claim 1. (Twice Amended) A 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I



I

wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R^1 stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a halo atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a C_{3-6} cycloalkyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two C_{1-4} alkyl group(s), a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen

C1
D1
cont

atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which latter is optionally substituted by 1 to 3 substituent(s), wherein the substituent consists of a C_{1-4} alkoxy group, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 substituents, wherein the substituent is a C_{1-4} alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the carbon atoms in positions 8 and 9, and in this case

R^1 represents a group of the formula

$-CO-(CH_2)_p-R^6$, wherein

R^6 stands for a halo atom, a phenoxy group, a C_{1-4} alkoxy group or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 mean, independently, a hydrogen atom, a guanyl group, a C_{3-6} cycloalkyl group or a C_{1-4} alkyl group which latter is optionally

C.1
D'
Cont

substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C_{1-4} alkoxy group, or

R^7 and R^8 form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group, or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C_{1-4} alkyl) group or a phenoxy(C_{1-4} alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a halo atom or a C_{1-4} alkoxy

C1

D1 cont

group, and, in case of the phenoxy(C_{1-4} alkyl) group, the alkyl group is optionally substituted by 1 or 2 hydroxy group(s),

p has a value of 0, 1 or 2,

R^2 stands for a nitro group, an amino group or a (C_{1-4} alkanoyl)amino group, with the proviso that

1) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group and p has a value of 0, then R^6 is different from a C_{1-4} alkoxy group,

2) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-4} alkyl group,

3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-4} alkyl group, and

4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-14} alkyl

group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,

and pharmaceutically suitable acid addition salts thereof.

Claim 2. (Twice Amended) A 1,3-dioxolo-[4,5-h][2,3] benzodiazepine compound as claimed in Claim 1, wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R^1 stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a chloro atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a cyclopropyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two methyl group(s), or a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and the heterocyclic group is optionally substituted by a phenyl group

which latter is optionally substituted by 1 to 3 methoxy groups, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 methoxy groups,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2,

R^2 stands for a nitro group or an amino group,

with the proviso that

1) if n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-4} alkyl group, and

2) if n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-4} alkyl group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,

and pharmaceutically suitable acid addition salts thereof.

Claim 5. (Twice Amended) A 8-methyl-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound as claimed in Claim 1, wherein in formula I

A forms together with B a valence bond between the carbon atoms in positions 8 and 9,

R^1 represents a group of the formula

$-CO-(CH_2)_p-R^6$, wherein

R^6 stands for a halo atom, a phenoxy group, a C_{1-4} alkoxy group or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 mean, independently, a hydrogen atom, a guanyl group, or a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a morpholino group, wherein the phenyl group is optionally substituted by one or two C_{1-2} alkoxy group(s), or

R^7 and R^8 form together with the adjacent nitrogen atom an oxopyrrolidinyl group, a phthalimido group or a saturated heterocyclic group having 5 or 6 members and comprising one or two nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 2 identical or different substituents(s) selected from the group consisting of a hydroxy

C2

group, a phenyl group, a phenoxy group, a phenyl(C_{1-4} alkyl) group or a phenoxy(C_{1-4} alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by a halo atom or a C_{1-4} alkoxy group,

p has a value of 0, 1 or 2,

R^2 stands for a nitro group or an amino group, with the proviso that

1) if R^2 stands for a nitro group or an amino group and p has a value of 0, then R^6 is different from a C_{1-4} alkoxy group, and

2) if R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-4} alkyl group,

and pharmaceutically suitable acid addition salts thereof.

Claim 6. (Twice Amended) A 8-methyl-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound as claimed in Claim 5, wherein

A forms together with B a valence bond between the carbon atoms in positions 8 and 9,

R^2 represents a nitro group or an amino group,

R^1 stands for a group of the formula

$-CO-(CH_2)_p-R^6$, wherein

C2

R^6 means a chloro atom, a phenoxy group, or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 represent, independently, a hydrogen atom, a guanyl group or a C_{1-3} alkyl group optionally substituted by a phenyl group, a dimethoxyphenyl group or a morpholino group, or

R^7 and R^8 form with the adjacent nitrogen atom, an oxopyrrolindinyl group, a phthalimido group or a saturated heterocyclic group having 5 or 6 members and comprising one or two nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by one or two identical or different substituent(s) selected from the group consisting of a hydroxy group, a methoxyphenyl group, a fluorophenyl group, a benzyl group or a (methoxy-phenoxy)-(hydroxypropyl) group,

p has a value of 0, 1 or 2, with the proviso that

if R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-3} alkyl group,

and pharmaceutically suitable acid addition salts thereof.

Claim 9. (Amended) A pharmaceutical composition comprising a 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I



I

wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R^1 stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a halo atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a C_{3-6} cycloalkyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two C_{1-4} alkyl group(s), a C_{1-4} alkyl group which is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or

C3 Q2 cont

a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which is optionally substituted by 1 to 3 substituent(s), wherein the substituent consists of a C_{1-4} alkoxy group, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 substituents, wherein the substituent is a C_{1-4} alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the carbon atoms in positions 8 and 9, and in this case

R^1 represents a group of the formula

$-CO-(CH_2)_p-R^6$, wherein

R^6 stands for a halo atom, a phenoxy group, a C_{1-4} alkoxy group or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 mean, independently, a hydrogen atom, a guanyl group, a C_{3-6} cycloalkyl group or a C_{1-4}

C3 D2 cont

alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C_{1-4} alkoxy group, or

R^7 and R^8 form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group which latter is optionally substituted, or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C_{1-4} alkyl) group or a phenoxy(C_{1-4} alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by 1 to 3 identical or different substituent(s),

C3
D2
cont

wherein the substituent is a halo atom or a C_{1-4} alkoxy group, and, in case of the phenoxy(C_{1-4} alkyl) group, the alkyl group is optionally substituted by 1 or 2 hydroxy group(s),

p has a value of 0, 1 or 2,

R^2 stands for a nitro group, an amino group or a (C_{1-4} alkanoyl)amino group, with the proviso that

1) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group and p has a value of 0, then R^6 is different from a C_{1-4} alkoxy group,

2) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-4} alkyl group,

3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-4} alkyl group, and

C 3

D 2 Cont

4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-4} alkyl group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-14} alkyl group,

or a pharmaceutically suitable acid addition salt thereof as the active ingredient and one or more conventional carrier(s).

Claim 10. (Twice Amended) A pharmaceutical composition as claimed in Claim 9 comprising a 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I, wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R^1 stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a chloro atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a cyclopropyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two methyl group(s), or a C_{1-4} alkyl group which latter is optionally substituted by a

C3
D2
cont

phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which latter is optionally substituted by 1 to 3 methoxy groups, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 methoxy groups,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2,

R^2 stands for a nitro group or an amino group, with the proviso that

1) if n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-4} alkyl group, and

2) if n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-4} alkyl group, then the other of

C3 D2 cont

R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,

or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

C4

Claim 13. (Twice Amended) A pharmaceutical composition as claimed in Claim 9 comprising an 8-methyl-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I, wherein

A forms together with B a valence bond between the carbon atoms in positions 8 and 9,

R^1 represents a group of the formula $-CO-(CH_2)_p-R^6$, wherein

R^6 stands for a halo atom, a phenoxy group, a C_{1-4} alkoxy group or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 mean, independently, a hydrogen atom, a guanyl group, or a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a morpholino group, wherein the phenyl group is optionally substituted by one or two C_{1-2} alkoxy group(s), or

R^7 and R^8 form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group or a saturated heterocyclic group having 5 or 6

C4

members and comprising one or two nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 2 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl (C_{1-4} alkyl) group or a phenoxy (C_{1-4} alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by a halo atom or a C_{1-4} alkoxy group,

p has a value of 0, 1 or 2,

R^2 stands for a nitro group or an amino group, with the proviso that

1) if R^2 stands for a nitro group or an amino group and p has a value of 0, then R^6 is different from a C_{1-4} alkoxy group, and

2) if R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-4} alkyl group,

or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

C4

Claim 14. (Twice Amended) A pharmaceutical composition as claimed in Claim 13 comprising an 8-methyl-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I, wherein

A forms together with B a valence bond between the carbon atoms in positions 8 and 9,

R^2 represents a nitro group or an amino group,

R^1 stands for a group of the formula

$-CO-(CH_2)_p-R^6$, wherein

R^6 means a chloro atom, a phenoxy group, or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 represent, independently, a hydrogen atom, a guanyl group or a C_{1-3} alkyl group optionally substituted by a phenyl group, a dimethoxyphenyl group or a morpholino group, or

R^7 and R^8 form with the adjacent nitrogen atom, an oxopyrrolindinyl group, a phthalimido group or a saturated heterocyclic group having 5 or 6 members and comprising one or two nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by one or two identical or different substituent(s) selected from the group consisting of a hydroxy group, a methoxyphenyl group, a fluorophenyl group,

C4

a benzyl group or a (methoxy-phenoxy)-(hydroxypropyl) group,

p has a value of 0, 1 or 2, with the proviso that

if R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-3} alkyl group,

or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

C5

Claim 16. (Twice Amended) A method of treatment in which a patient suffering from epilepsy or being in a state after stroke is treated with a non-toxic dose of a 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I,



I

wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R^1 stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a halo atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a C_{3-6} cycloalkyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two C_{1-4} alkyl group(s), a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by a phenyl group which latter is optionally substituted by 1 to 3 substituent(s), wherein the substituent consists of a C_{1-4} alkoxy group, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 substituents, wherein the substituent is a C_{1-4} alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the carbon atoms in positions 8 and 9, and in this case

R^1 represents a group of the formula

$-CO-(CH_2)_p-R^6$, wherein

R^6 stands for a halo atom, a phenoxy group, a C_{1-4} alkoxy group or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 mean, independently, a hydrogen atom, a guanyl group, a C_{3-6} cycloalkyl group or a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C_{1-4} alkoxy group, or

R^7 and R^8 form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group, or a saturated heterocyclic group having 5 or 6 members and comprising one or

more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C_{1-4} alkyl) group or a phenoxy(C_{1-4} alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a halo atom or a C_{1-4} alkoxy group, and, in case of the phenoxy(C_{1-4} alkyl) group, the alkyl group is optionally substituted by 1 or 2 hydroxy group(s),

p has a value of 0, 1 or 2,

R^2 stands for a nitro group, an amino group or a (C_{1-4} alkanoyl)amino group, with the proviso that

1) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group and p has a value of 0, then R^6 is different from a C_{1-4} alkoxy group,

2) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^8 is different from a hydrogen atom or a C_{1-4} alkyl group,

3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-14} alkyl group, and

4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a hydrogen atom or a C_{1-14} alkyl group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,

or a pharmaceutically suitable acid addition salt thereof.

Claim 17. (Twice Amended) A process for preparing a pharmaceutical composition suitable for the treatment of epilepsy or a state after stroke, characterized in that a 1,3-dioxolo-[4,5-h][2,3]benzodiazepine compound of the formula I,



I

wherein

A represents a hydrogen atom,

B means a hydrogen atom,

R^1 stands for a group of the formula

$-(CH_2)_n-CO-(CH_2)_m-R$, wherein

R represents a halo atom, a pyridyl group or a group of the formula $-NR^3R^4$, wherein

R^3 and R^4 mean, independently, a hydrogen atom, a C_{3-6} cycloalkyl group, a C_{1-4} alkoxy group, an amino group, a phenyl group optionally substituted by one or two C_{1-4} alkyl group(s), a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and comprising 1 to 3 nitrogen atom(s) or a nitrogen atom and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted

by a phenyl group which latter is optionally substituted by 1 to 3 substituent(s), wherein the substituent consists of a C_{1-4} alkoxy group, or

R^3 and R^4 form, with the adjacent nitrogen atom and optionally with a further nitrogen atom or an oxygen atom, a saturated or unsaturated heterocyclic group having 5 or 6 members, being optionally substituted by a phenyl group that is optionally substituted by 1 to 3 substituents, wherein the substituent is a C_{1-4} alkoxy group,

n has a value of 0, 1 or 2,

m has a value of 0, 1 or 2, or

A forms together with B a valence bond between the carbon atoms in positions 8 and 9, and in this case

R^1 represents a group of the formula

$-CO-(CH_2)_p-R^6$, wherein

R^6 stands for a halo atom, a phenoxy group, a C_{1-4} alkoxy group or a group of the formula $-NR^7R^8$, wherein

R^7 and R^8 mean, independently, a hydrogen atom, a guanyl group, a C_{3-6} cycloalkyl group or a C_{1-4} alkyl group which latter is optionally substituted by a phenyl group or a saturated heterocyclic group having 5 or 6 members and

comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, wherein the phenyl group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a C_{1-4} alkoxy group, or

R^7 and R^8 form together with the adjacent nitrogen atom, an oxopyrrolidinyl group, a phthalimido group, or a saturated heterocyclic group having 5 or 6 members and comprising one or more nitrogen atom(s) or a nitrogen and an oxygen atom as the heteroatom, and said heterocyclic group is optionally substituted by 1 to 3 identical or different substituent(s) selected from the group consisting of a hydroxy group, a phenyl group, a phenoxy group, a phenyl(C_{1-4} alkyl) group or a phenoxy(C_{1-4} alkyl) group, wherein in case of the substituents listed the phenyl or phenoxy group is optionally substituted by 1 to 3 identical or different substituent(s), wherein the substituent is a halo atom or a C_{1-4} alkoxy group, and, in case of the phenoxy(C_{1-4} alkyl)

group, the alkyl group is optionally substituted by 1 or 2 hydroxy group(s),

p has a value of 0, 1 or 2,

R^2 stands for a nitro group, an amino group or a (C_{1-4} alkanoyl)amino group, with the proviso that

1) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group and p has a value of 0, then R^6 is different from a C_{1-4} alkoxy group,

2) if A forms together with B a valence bond, R^2 stands for a nitro group or an amino group, p has a value of 0 or 1, and R^6 represents a group of the formula $-NR^7R^8$, then one of R^7 and R^6 is different from a hydrogen atom or a C_{1-4} alkyl group,

3) if each of A and B stands for a hydrogen atom, n and m have a value of 0, then one of R^3 and R^4 represents a hydrogen atom, and the other of R^3 and R^4 is different from a hydrogen atom, a phenyl group or a C_{1-14} alkyl group, and

4) if each of A and B stands for a hydrogen atom, n has a value of 0, m has a value of 1 or 2, and one of R^3 and R^4 stands for a

hydrogen atom or a C_{1-4} alkyl group, then the other of R^3 and R^4 is different from a hydrogen atom or a C_{1-4} alkyl group,

C5
D3
cont

or a pharmaceutically suitable acid addition salt thereof, together with one or more conventional carrier(s), is converted to a pharmaceutical composition.